Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Journal of Psychiatry& Neuroscience 2019 PRINT & DIGITAL MEDIA KIT
2
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
The Journal of Psychiatry & Neuroscience publishes original research articles and review papers in psychiatry and in neuroscience
that advance the understanding of the mechanisms involved in the etiology and treatment of psychiatric disorders. This includes studies on patients with psychiatric disorders, healthy humans and experimental animals, as well as studies in vitro and clinical trials with a mechanistic component.
�� Published 6 times per year
�� Full circulation to psychiatrists, neurologists and selected family doctors with an interest in psychiatry
Print circulation dataJPN offers the most comprehensive circulation to these specialist groups
Psychiatry .................................................................... 3491
Neurology ...................................................................... 706
GP/FM (with an interest in psychiatry and/or neurology) ...... 1198
Readership highlights�� JPN reaches more prescribing physicians than other journals in this category
�� JPN readers see more patients on a daily basis
�� JPN ranks as the #2 best-read specialist publication for psychiatrists
�� JPN has particular strength among GP/FM readers with an interest in psychiatry
�� JPN is highly valued by the psychiatry/neurology reader and is a quality buy
Source: Medical Media Study, 2013
FeaturesOriginal research articles on factors contributing to illness, the mechanism of action of various drugs and treatment options for common psychiatric illnesses.
Reviews provide a broad understanding of relevant research on mental disorders and the science behind new medications and practice recommendations.
Editorial and commentaries provide a forum for editors and experts in their fields to comment on emerging issues.
Psychopharmacology for the Clinician offers suggested approaches for clinicians treating specific conditions (opposite inside back cover).
iSto
ck
3
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
Cover rates (4-colour only)Inside front cover $5740
Inside back cover $5495
Outside back cover $6640
Half cover overwrap $5585
Tip on (supplied) $7350
Bellyband (supplied) $12,500
For other guaranteed positions add 25% of the earned black-and-white rates.
Table of contents bootlug: $2400 per insertion (includes colour)
Polybag opportunities available upon request.
* When fair balance runs adjacent to display ad in 4c, an additional colour charge applies.
Career/classified word advertising rates40 words or fewer $120
Each additional word $1.20
Box frame $25
Special display $205
Reply box number $20
SIZE 1X 6 X 12 X Fair balance* (b/w)
1 page $4810 $4690 $4370 $1600
2/3 page $4180 $4070 $3970 $1510
1/2 page v/h $3750 $3645 $3535 $1285
1/3 page $3315 $3210 $3110 $1220
Double-page spread $8350
Four-colour advertising rates
Journal insertsRequirements: Full page only. Single-leaf inserts maximum 80 lb. Multiple-page inserts (maximum 70 lb.) to be supplied folded. All inserts to be supplied untrim med.
Un trimmed size
8 3/8˝ x 11 1/8˝ (provides 1/8˝ head trim)
Trimmed size 8 1/8˝ x 10 7/8˝
Supplied advertising inserts2 pages ................. $4750 4 pages ................. $9500
Other types of insert stock subject to publisher’s approval. Perforating, embossing and die-cutting permitted, provided they do not alter outside dimensions of insert.
iSto
ck
4
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
Digital specifications for display advertising Digital files are required and must meet the following specifications. All material is held for one year after publication.
Trimmed size of publication 8 1/8˝ x 10 7/8˝
Bleed page 8 3/8˝ x 11 1/8˝
Live area 7˝ x 9 1/2˝
File formats accepted�� Adobe Acrobat PDF
Distiller Settings are posted on the CMAJ Web site (see end of this section).
�� High resolution CMYK PDF (no spot or pantone colour)
Technical specifications, including digital specifications�� Display Advertising: http://www.cmaj.ca/pdfs/display-e.pdf
�� PDF Export Settings: http://www.cmaj.ca/pdfs/export-e.pdf
Issue and closing datesISSUE DATE AD/MATERIAL DEADLINE
January 2019 December 10, 2018
March February 11
May April 15
July June 10
September August 12
November October 15
iSto
ck
5
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
Ad specs
Binding: Saddle-stitchBootlug Trim 7” x 1 5/8” No Bleed Live 7” x 1 5/8”
1/3 page horizontal Trim 8 1/8” x 3 5/8” Bleed 8 3/8” x 3 7/8” Live 7” x 3”
1/3 page vertical Trim 2 5/8” x 10 7/8” Bleed 2 7/8” x 11 1/8” Live 2 1/4” x 9 1/2”
1/2 page horizontal Trim 8 1/8” x 5 7/16” Bleed 8 3/8” x 5 11/16” Live 7” x 4 5/8”
1/2 page vertical Trim 4 1/16” x 10 7/8” Bleed 4 5/16” x 11 1/8” Live 3 3/8” x 9 1/2”
2/3 page vertical Trim 5 3/8” x 10 7/8” Bleed 5 5/8” x 11 1/8” Live 4 5/8” x 9 1/2”
Full page Trim 8 1/8” x 10 7/8” Bleed 8 3/8” x 11 1/8” Live 7” x 9 1/2”
Double-page Spread Trim 16 1/4” x 10 7/8” Bleed 16 1/2” x 11 1/8” Live 7” x 9 1/2” (on each full page)
Functional connectivity and CBT for OCD
J Psychiatry Neurosci 2017;42(6) 385
21. Murphy K, Birn RM, Handwerker DA, et al. The impact of global signal regression on resting state correlations: Are anti-correlated networks introduced? Neuroimage 2009;44:893-905.
22. Eickhoff SB, Paus T, Caspers S, et al. Assignment of functional acti-vations to probabilistic cytoarchitectonic areas revisited. Neuroimage 2007;36:511-21.
23. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling sys-tem for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968-80.
24. Kozak MJ, Foa EB. Mastery of your obsessive-compulsive disorder. San Antonio (TX): Psychological Corp; 1997.
25. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989;46:1006.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Knopp J, Knowles S, Bee P, et al. A systematic review of predictors and moderators of response to psychological therapies in OCD: Do we have enough empirical evidence to target treatment? Clin Psychol Rev 2013;33:1067-81.
28. Brown VM, Haswell CC, Gold AL, et al. Altered resting-state functional connectivity of basolateral and centromedial amygdala complexes in posttraumatic stress disorder. Neuropsychopharmacol-ogy 2014;39:351-9.
29. Siegle GJ, Carter CS, Thase ME. Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry 2006;163:735-8.
30. Siegle GJ, Thompson WK, Collier A, et al. Toward clinically useful neuroimaging in depression treatment prognostic utility of sub-genual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteris-tics. Arch Gen Psychiatry 2012;69:913-24.
31. Linnman C, Zeidan MA, Furtak SC, et al. Resting amygdala and medial prefrontal metabolism predicts functional activation of the fear extinction circuit. Am J Psychiatry 2012;169:415-23.
32. Maren S. Synaptic mechanisms of associative memory in the amygdala. Neuron 2005;47:783-6.
33. LeDoux J. Fear and the brain: Where have we been, and where are we going? Biol Psychiatry 1998;44:1229-38.
34. Bishop SJ. Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci 2007;11:307-16.
35. Shehzad Z, Kelly AMC, Reiss PT, et al. The resting brain: uncon-strained yet reliable. Cereb Cortex 2009;19:2209–29.
36. Boschen MJ, Drummond LM. Community treatment of severe, re-fractory obsessive-compulsive disorder. Behav Res Ther 2012;50: 203-9.
37. Wardlaw JM, Brindle W, Casado AM, et al. A systematic re-view of the utility of 1.5 versus 3 Tesla magnetic resonance brain imaging in clinical practice and research. Eur Radiol 2012; 22: 2295-303.
38. Vogel S, Klumpers F, Krugers HJ, et al. Blocking the mineralocorti-coid receptor in humans prevents the stress-induced enhancement of centromedial amygdala connectivity with the dorsal striatum. Neuropsychopharmacology 2015;40:947-56.
39. Mataix-Cols D, do Rosario-Campos MC, Leckman JF. A multi-dimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005;162:228-38.
JPN’s top viewed articles*
1. How to increase serotonin in the human brain without drugs
Young J Psychiatry Neurosci 2007;32(6):394–9
2. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Dean et al. J Psychiatry Neurosci 2011;36(2):78–86
3. Emotional learning during dissociative states in borderline personality disorder
Ebner-Priemer et al. J Psychiatry Neurosci 2009;34(3):214–22
4. L-Tyrosine to alleviate the effects of stress? Young
J Psychiatry Neurosci 2007;32(3):224
5. Why is depression more prevalent in women? Albert J Psychiatry Neurosci 2015;40(4):219–21
6. What is the best treatment for bipolar depression? Young J Psychiatry Neurosci 2008;33(6):487–8
7. Amygdala and insula response to emotional images in patients with generalized social anxiety disorder
Shah et al. J Psychiatry Neurosci 2009;34(4):296–302
8. Folate and depression: a neglected problem Young J Psychiatry Neurosci 2007;32(2):80–2
9. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder
MacQueen et al. J Psychiatry Neurosci 2007;32(4):241–9
10. On the neurobiology of hallucinations Boksa
J Psychiatry Neurosci 2009;34(4):260–2
* Based on page views on PubMed Central of content published in the last 10 years. Updated Oct. 11, 2017.
baso-fullana.indd 385 2017-10-24 11:43 AM
Resting-state networks and CSF biomarkers in Alzheimer disease
J Psychiatry Neurosci 2017;42(6) 377
28. Sala-Llonch R, Bosch B, Arenaza-Urquijo EM, et al. Greater default-mode network abnormalities compared to high order visual processing systems in amnestic mild cognitive impairment: an in-tegrated multi-modal MRI study. J Alzheimers Dis 2010;22:523-39.
29. Hansen NL, Lauritzen M, Mortensen EL, et al. Subclinical cogni-tive decline in middle-age is associated with reduced task-induced deactivation of the brain’s default mode network. Hum Brain Mapp 2014;35:4488-98.
30. Liang Z, King J, Zhang N. Anticorrelated resting-state functional connectivity in awake rat brain. Neuroimage 2012;59:1190-9.
31. Kann O. The interneuron energy hypothesis: implications for brain disease. Neurobiol Dis 2016;90:75-85.
32. Lim HK, Nebes R, Snitz B, et al. Regional amyloid burden and in-trinsic connectivity networks in cognitively normal elderly sub-jects. Brain 2014;137:3327-38.
33. Elman JA, Madison CM, Baker SL, et al. Effects of beta-amyloid on resting state functional connectivity within and between networks reflect known patterns of regional vulnerability. Cereb Cortex 2016 ;26:695-707.
34. Sepulcre J, Sabuncu MR, Becker A, et al. In vivo characterization of the early states of the amyloid-beta network. Brain 2013;136:2239-52.
35. Myers N, Pasquini L, Gottler J, et al. Within-patient correspondence of amyloid-beta and intrinsic network connectivity in Alzheimer’s disease. Brain 2014;37:3137-52.
36. Koch K, Myers NE, Gottler J, et al. Disrupted intrinsic networks link amyloid-beta pathology and impaired cognition in prodromal Alzheimer’s disease. Cereb Cortex 2015.
37. Li X, Li TQ, Andreasen N, et al. Ratio of Abeta42/P-tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep 2013;3:1339.
38. Andreasen N, Vanmechelen E, Vanderstichele H, et al. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts develop-ment of Alzheimer’s disease in patients with mild cognitive impair-ment. Acta Neurol Scand Suppl 2003;179:47-51.
39. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau pro-tein correlates with neocortical neurofibrillary pathology in Al-zheimer’s disease. Brain 2006;129:3035-41.
40. Walker LC, Diamond MI, Duff KE, et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013;70:304-10.
41. Han SD, Gruhl J, Beckett L, et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s disease. Brain Imaging Behav 2012;6:610-20.
Call for submissionsHave expertise treating patients with psychiatric disorders? Share it with clinicians in a Psychopharmacology for the Clinician column. Columns are 650 words and include a clinical vignette showcasing a topic of interest. Cases should have a level of complexity or novelty that will help clinicians make treatment decisions in situations that are not routine, or where new evidence is available but not widely known.
Why write for JPN?• JPN is the highest ranking open access journal in biological psychiatry• Psychopharmacology for the Clinician columns are the most downloaded feature of JPN and archives are available inde�nitely on jpn.ca and in PubMed Central
Submit columns online at https://mc.manuscriptcentral.com/jpn. View previous columns at https://jpn.ca/psychopharmacology-for-the-clinician/
JPN-submission-halfpage.pdf 1 2017-10-18 1:12 PM
intra-weiler.indd 377 2017-10-24 9:54 AM
1/3 page vertical 2 5/8” x 10 7/8”
2/3 page vertical 5 3/8” x 10 7/8”
Psychiatric genetics — Does diagnosis matter?
J Psychiatry Neurosci 2017;42(5) 293
Conclusion
Genetic research has not yet led to major changes in psychi atric practice. At the same time, it has played an im-portant role in highlighting the complexity of psychiatric disorders and in challenging current psychiatric nosology.
Affiliations: From the Department of Psychiatry, Dalhousie Uni-versity, Halifax, NS, Canada.
Competing interests: None declared.
References
1. Propping P. Genetic disorders presenting as “schizophrenia”. Karl Bonhoeffer’s early view of the psychoses in the light of med-ical genetics. Hum Genet 1983;65:1-10.
2. Cross-disorder group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychi-atric disorders: a genome-wide analysis. Lancet 2013;20:1371-9.
3. Lee SH, Ripke S, Neale BM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45:984-94.
4. Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: from polygenic to omnigenic. Cell 2017;169:1177-86.
5. Visscher PM, Wray NR, Zhang Q, et al. 10 years of GWAS discov-ery: biology, function, and translation. Am J Hum Genet 2017; 101:5-22.
6. Regier DA, Narrow WE, Clarke DE, et al. DSM-5 field trials in the United States and Canada, part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013;170:59-70.
7. Schwartz JE, Fennig S, Tanenberg-Karant M, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry 2000;57:593-600.
8. Song J, Bergen SE, Kuja-Halkola R, et al. Bipolar disorder and its relation to major psychiatric disorders: a family-based study in the Swedish population. Bipolar Disord 2015;17:184-93.
9. Cardno AG, Rijsdijk FV, Sham PC, et al. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002; 159:539-45.
10. Nordsletten AE, Larsson H, Crowley JJ, et al. Patterns of nonran-dom mating within and across 11 major psychiatric disorders. JAMA Psychiatry 2016;73:354-61.
11. Duffy A, Alda M, Kutcher S, et al. A prospective study of the off-spring of bipolar parents responsive and nonresponsive to lithium treatment. J Clin Psychiatry 2002;63:1171-8.
12. Manchia M, Cullis J, Turecki G, et al. The impact of phenotypic and genetic heterogeneity on results of genome wide association studies of complex diseases. PLoS ONE 2013;8:e76295.
13. Robins E, Guze SB. Establishment of diagnostic validity in psychi-atric illness: its application to schizophrenia. Am J Psychiatry 1970; 126:983-7.
14. Franchini L, Serretti A, Gasperini M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998;32:255-9.
15. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002;63:942-7.
We believe in open access to research
To ensure continued worldwide free access to all JPN content, Research and Review articles accepted for publication are subject to an article processing fee of $1750 (Canadian funds), payable on acceptance.
Benefits of open access
• For researchers and institutions: increased visibility, usage and impact for their work• For government: a better return on investment for funding research• For society: efficient, effective patient care resulting in better outcomes
JPN has an impact factor of 5.16 (2016 ISI data), making it the highest-ranking open access journal in both the psychiatry and neuroscience categories. JPN articles are available free of charge on the journal website (jpn.ca) and in PubMed Central.
edit-september.indd 293 2017-08-21 2:04 PM
Bhikram et al.
306 J Psychiatry Neurosci 2017;42(5)
49. Fusar-Poli P, Placentino A, Carletti F, et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 2009;34:418-32.
50. Jabbi M, Bastiaansen J, Keysers C, et al. A common anterior insula rep-resentation of disgust observation, experience and imagination shows divergent functional connectivity pathways. PLoS One 2008; 3:e2939.
51. Wicker B, Keysers C, Plailly J, et al. Both of us disgusted in my in-sula: the common neural basis of seeing and feeling disgust. Neuron 2003;40:655-64.
52. Royet J, Plailly J, Delon-Martin C, et al. fMRI of emotional re-sponses to odors: influence of hedonic valence and judgment, handedness, and gender. Neuroimage 2003;20:713-28.
53. Husted DS, Shapira NA, Goodman WK. The neurocircuitry of obsessive-compulsive disorder and disgust. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:389-99.
54. Shapira NA, Liu Y, He AG, et al. Brain activation by disgust- inducing pictures in obsessive-compulsive disorder. Biol Psychiatry 2003;54:751-6.
55. Lawrence NS, An SK, Mataix-Cols D, et al. Neural responses to fa-cial expressions of disgust but not fear are modulated by washing symptoms in OCD. Biol Psychiatry 2007;61:1072-80.
56. Phillips ML, Young AW, Senior C, et al. A specific neural substrate for perceiving facial expressions of disgust. Nature 1997;389:495-8.
57. Fitzgerald DA, Posse S, Moore GJ, et al. Neural correlates of internally-generated disgust via autobiographical recall: a functional magnetic resonance imaging investigation. Neurosci Lett 2004;370:91-6.
58. Sprengelmeyer R. Recognition of facial expressions: selective im-pairment of specific emotions in Huntington’s disease. Cogn Neuropsychol 1997;14:839-79.
59. Wang K, Hoosain R, Yang R, et al. Impairment of recognition of disgust in chinese with Huntington’s or Wilson’s disease. Neuropsychologia 2003;41:527-37.
60. Sprengelmeyer R, Young AW, Mahn K, et al. Facial expression rec-ognition in people with medicated and unmedicated Parkinson’s disease. Neuropsychologia 2003;41:1047-57.
61. Evans DW, Lewis MD, Iobst E. The role of the orbitofrontal cortex in normally developing compulsive-like behaviors and obsessive-compulsive disorder. Brain Cogn 2004;55:220-34.
62. Del Casale A, Kotzalidis GD, Rapinesi C, et al. Functional neuro imaging in obsessive-compulsive disorder. Neuropsychobiology 2011; 64:61-85.
63. Kwon JS, Jang JH, Choi JS, et al. Neuroimaging in obsessive– compulsive disorder. Expert Rev Neurother 2009;9:255-69.
64. Rotge JY, Guehl D, Dilharreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci 2008;33:405-12.
65. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural cor-relates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004;61:564-76.
66. Adler CM, McDonough-Ryan P, Sax KW, et al. fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. J Psychiatr Res 2000;34:317-24.
67. Breiter HC, Rauch SL, Kwong KK, et al. Functional magnetic res-onance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996;53:595-606.
68. Nakao T, Nakagawa A, Yoshiura T, et al. Brain activation of pa-tients with obsessive-compulsive disorder during neuropsycho-logical and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 2005;57:901-10.
69. Kang DH, Kwon JS, Kim J, et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 2003;107:291-7.
70. Saxena S, Brody AL, Maidment KM, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999;21:683-93.
71. Stein DJ, Arya M, Pietrini P, et al. Neurocircuitry of disgust and anxiety in obsessive-compulsive disorder: a positron emission tomography study. Metab Brain Dis 2006;21:255-65.
72. Schienle A, Schäfer A, Stark R, et al. Neural responses of OCD pa-tients towards disorder-relevant, generally disgust-inducing and fear-inducing pictures. Int J Psychophysiol 2005;57:69-77.
73. Jhung K, Ku J, Kim SJ, et al. Distinct functional connectivity of limbic network in the washing type obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2014;53:149-55.
74. Nakamae T, Narumoto J, Shibata K, et al. Alteration of fractional anisotropy and apparent diffusion coefficient in obsessive- compulsive disorder: a diffusion tensor imaging study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1221-6.
75. Buyukturkoglu K, Roettgers H, Sommer J, et al. Self-regulation of anterior insula with real-time fMRI and its behavioral effects in obsessive-compulsive disorder: a feasibility study. PLoS One 2015; 10:e0135872.
76. Harrison BJ, Pujol J, Cardoner N, et al. Brain corticostriatal systems and the major clinical symptom dimensions of obsessive-compulsive disorder. Biol Psychiatry 2013;73:321-8.
77. Adams T, Badour C, Lohr J, et al. Treatment of disgust-related psychopathology. Ann Psychother Integr Health. 2013;16:26-33.
JPN Commentaries are an article type similar to reviews, but are designed to make a point about a topic without reviewing the topic comprehensively.
To submit a commentary to JPN, visit our online submission and peer review system at https://mc.manuscriptcentral.com/jpn
Visit JPN’s archivesFull-text PDFs going back to 1991 are available at
pubmedcentral.com
ocd-bhikram.indd 306 2017-08-21 2:33 PM
Bootlug 7” X 1 5/8” 1/3 page horizontal 8 1/8” X 3 5/8”
1/2 page horizontal 8 1/8” x 5 7/16”
1/2 page vertical 4 1/16” x 10 7/8”
Full Page 8 1/8” x 10 7/8”
6
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
Digital options for 2019 | JPN eTOC Complete “electronic table of contents” delivered 6x per year to 5500 Psychiatrists, Neurologists and General Practice physicians with an interest in these specialities. Banner ad positions available.
A gated service – PAAB rules for ads to physicians apply
Please contact your sales representative for material deadlines and “send”dates
jpn.caWeb advertising rates are based on the actual number of ad impressions (as measured by Google ad monitoring software) on www.jpn.ca. This site is a full, free, open access journal. Direct to consumer ad rules apply to journal site.
Big box 300 x 300 pixels
Banner advertising sizes Top leaderboard
728 x 90 or 728 x 180 pixels $2850 net
Big box
300 x 250 or 300 x 300 pixels $2500 net
Lower leaderboard
728 x 90 or 728 x 180 pixels $2250 net
JPN.CA Banner advertising sizes Leaderboard 728 x 90 pixels $80/M ad impressions
Big box 300 x 200 pixels $80/M ad impressions
Top Leaderboard 728 x 90 pixels
Top Leaderboard 728 x 90 pixels
Lower Leaderboard 728 x 90 pixels
Big box 200 x 200 pixels
7
2019 PRINT & DIGITAL MEDIA KIT | JOURNAL OF PSYCHIATRY & NEUROSCIENCE
Career/classified advertising salesLaurie McLeod x 8460 or Susan Ritchie x 8475 [email protected]
Tel: 613-731-8610 or 800-663-7336
Advertising sales and Production enquiriesInsert and shipping enquiries, display advertising material
Trish Sullivan Senior Advertising Sales Representative [email protected]
Cell: 905-330-8770
Publisher, InterimHolly Bodger [email protected]
Sales co-ordinatorTracey Hopcroft [email protected]
Trademarks of the Canadian Medical Association used under licence.
iSto
ck
Payment informationCOMMISSIONAgency commission of 15% allowed to recognized agencies only.
CANADIAN CLIENTSAll invoices are payable to Joule Inc., a Canadian Medical Association company.
CLIENTS OUTSIDE CANADAAdvertisements from outside Canada must be prepaid. Major credit cards, cheques, money orders and wire transfers accepted.
GROUP